Abstract
The Statistics Expert Group was convened at the request of the Infected Blood Inquiry to provide estimates of the number of infections and deaths from bloodborne infections including hepatitis B virus; human immunodeficiency virus; hepatitis C virus and variant Creutzfeldt Jakob disease, as a direct result of contaminated blood and blood products administered in the United Kingdom of Great Britain and Northern Ireland (UK). In the absence of databases of HCV infections and related deaths for all nations of the UK, a statistical model was required to estimate the number of infections and subsequent deaths from HCV acquired from blood transfusions throughout January 1970 – August 1991.
We present this statistical model in detail alongside the results of its application to each of the four nations in the UK. We estimated that 26,800 people (95% uncertainty interval 21,300 – 38,800) throughout the UK were chronically infected with HCV because of contaminated blood transfusions between January 1970 and August 1991. The number of deaths up to the end of 2019 that occurred as a result of this chronic infection is estimated to be 1,820 (95% uncertainty interval 650 – 3,320).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SH, RM, SMB and DJS gratefully acknowledge financial support from the IBI to undertake this work. This work was also supported by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections, a partnership between UKHSA, University of Oxford, University of Liverpool and Liverpool School of Tropical Medicine [grant number NIHR200907 supporting SH, RM and CAD]; and the MRC Centre for Global Infectious Disease Analysis [grant number MR/R015600/1 supporting CAD], which is jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth and Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union (EU). Disclaimer: `The views expressed are those of the authors and not necessarily those of the Infected Blood Inquiry, United Kingdom (UK) Department of Health and Social Care, EU, FCDO, MRC, National Health Service, NIHR, or PHE. The funding bodies had no role in the design of the study, analysis and interpretation of data and in writing the manuscript.`
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵+ Joint senior authors
Data Availability
All code is available at: https://github.com/ruthmccabe/IBI-SEG-HCV-model. Data which we are able to share are included throughout the manuscript and supplementary material.
